Search Results
Tofersen and the Future of ALS Drug Development
Why FDA Decision on Tofersen Matters
Tofersen Approved for SOD1-ALS
Tofersen and the FDA Approval Process
FDA Approves Biogen’s Tofersen Drug for Rare Form of ALS
ALS research that can stop the development of the disease
Tofersen (Qalsody), First FDA Approved Medication For SOD1-ALS (Amyotrophic Lateral Sclerosis)
2021 Neuroscience Symposium | Breaking Update: ALS Clinical Trials
7th Annual ALS ONE Research Symposium: Day 1 – Keynote Speaker: Dr. Sheena Chew, MD
Oral Testimony to the FDA Advisory Committee on the Approval of tofersen
7 generations battling ALS: Rockford family's new hope with experimental drug
Tofersen helps people with ALS caused by an SOD1 mutation
